Evotec AG (NASDAQ:EVTCY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

A number of other equities analysts also recently commented on the company. Berenberg Bank downgraded Evotec AG from a “buy” rating to a “hold” rating in a research note on Tuesday, June 6th. DZ Bank AG restated a “sell” rating on shares of Evotec AG in a research note on Wednesday, July 12th.

Evotec AG (NASDAQ:EVTCY) last posted its quarterly earnings results on Thursday, August 10th. The company reported $0.04 EPS for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.03). The company had revenue of $58.52 million during the quarter, compared to analyst estimates of $50.06 million.

ILLEGAL ACTIVITY NOTICE: “Evotec AG (EVTCY) Downgraded to Hold at Zacks Investment Research” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/21/evotec-ag-evtcy-downgraded-to-hold-at-zacks-investment-research.html.

Evotec AG Company Profile

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Get a free copy of the Zacks research report on Evotec AG (EVTCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.